secwatch.observer — SEC 8-K summary
======================================

Issuer:     OptimizeRx Corp (OPRX)
CIK:        0001448431
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001213900-22-070127
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OptimizeRx Q3 revenue $15.1M, down 6% YoY; GAAP loss $0.19/share; FY guidance reaffirmed
--------------------------------------------------------------------------------

- Revenue $15.1M (-6% YoY, +8% QoQ); gross margin improved to 62% from 56%.
- GAAP net loss $3.5M ($0.19 per share); non-GAAP net income $1.3M ($0.07 per share).
- Operating cash flow $7.9M in first nine months; cash & investments $78.8M.
- FY2022 guidance reiterated: revenue $62M-$68M, gross margin 59%-62%.
- Repurchased 1.1M shares YTD at average price of $16.70 per share.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1448431/000121390022070127/0001213900-22-070127-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1448431/000121390022070127/ea168208-8k_optimizerx.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-070127

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer